As of 2025-08-10, the Intrinsic Value of Australian Pharmaceutical Industries Ltd (API.AX) is 14.29 AUD. This API.AX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.53 AUD, the upside of Australian Pharmaceutical Industries Ltd is 834.20%.
The range of the Intrinsic Value is 7.47 - 125.27 AUD
Based on its market price of 1.53 AUD and our intrinsic valuation, Australian Pharmaceutical Industries Ltd (API.AX) is undervalued by 834.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 7.47 - 125.27 | 14.29 | 834.2% |
| DCF (Growth 10y) | 9.17 - 140.63 | 16.83 | 1000.1% |
| DCF (EBITDA 5y) | 3.73 - 6.65 | 4.72 | 208.8% |
| DCF (EBITDA 10y) | 5.29 - 8.97 | 6.58 | 330.0% |
| Fair Value | 0.29 - 0.29 | 0.29 | -80.92% |
| P/E | (0.11) - 1.34 | 0.50 | -67.1% |
| EV/EBITDA | 0.02 - 1.46 | 0.67 | -56.3% |
| EPV | (0.71) - (0.79) | (0.75) | -149.0% |
| DDM - Stable | (0.15) - (0.97) | (0.56) | -136.7% |
| DDM - Multi | 5.46 - 27.82 | 9.19 | 500.9% |
| Market Cap (mil) | 753.76 |
| Beta | 0.36 |
| Outstanding shares (mil) | 492.66 |
| Enterprise Value (mil) | 1,029.14 |
| Market risk premium | 4.74% |
| Cost of Equity | 6.86% |
| Cost of Debt | 5.50% |
| WACC | 5.88% |